Global Controlled Release Drug Delivery Market - 2023-2030

Global Controlled Release Drug Delivery Market - 2023-2030

The global controlled release drug delivery market reached US$ 50.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 101.3 billion by 2030. The global controlled release drug delivery market is expected to exhibit a CAGR of 9.2% during the forecast period (2023-2030).

Controlled release systems enable the sustained and regulated release of medications over a long period of time. This regulated distribution helps to keep therapeutic medication concentrations within the appropriate range, maximising therapy efficacy. It can increase patient compliance by reducing drug administration frequency and guaranteeing continuous drug supply, resulting in better therapeutic outcomes.

Additionally, pharmaceutical companies, who operate in a fiercely competitive and fragmented industry, have greatly boosted demand as a result of their proactive response to evolving market demands and continued investments in developing controlled-release drug delivery methods.

Market Dynamics
The Increasing Geriatric and Pediatric Population will Drive the Market Growth

The growing geriatric and paediatric population worldwide is one of the primary reasons driving market expansion, owing largely to non-adherence to prescription regimens, which is quite common among these age groups. Geriatric people have impaired physical, mental, and biological functioning, which affect their medication usage.

For instance, according to WHO, all countries have significant challenges in ensuring that their health and social systems are prepared to capitalise on this demographic transformation. By 2050, 80% of the elderly will live in low- and middle-income countries. The population is ageing at a considerably higher rate than in the past.

In 2020, the number of persons aged 60 and more will outnumber youngsters under the age of five. Between 2015 and 2050, the fraction of the global population over the age of 60 will nearly double, from 12% to 22%. As a result, the growing senior population will aid to boost market expansion.

Raising Initiatives And Strategies By the Key Companies also Drive the Market Growth

The increased activities and strategies implemented by key players to deal with the growing demand for controlled release medicine delivery are also predicted to fuel market expansion. For instance, in October 2020, Evonik Industries AG, a German pharmaceutical company, has introduced Eudratec Fasteric, an oral drug delivery technology that improves intestinal absorption for oral drug products that target sites in the upper small intestine with a narrow absorption window.

Furthermore, it can be processed rapidly and efficiently using conventional instruments and is compatible with a wide range of oral dose forms, including multiarticulate, tablets, and capsules. The market will expand as a result of the aforementioned factors.

Lack of On-Demand Release will Hamper the Market Growth
Developing on-demand controlled release drug delivery systems is technically challenging. It requires the integration of sophisticated mechanisms to trigger drug release in response to specific stimuli or external signals. Designing such systems with precise control over drug release rates and dosages is complex and often requires advanced materials and engineering techniques.

Developing on-demand controlled release systems can be costly due to the need for specialized materials, technologies, and manufacturing processes. Additionally, the complexity of these systems may increase the production costs, making them less affordable and accessible for widespread use. Thus, above factors will restrict the market growth.

COVID-19 Impact Analysis
The COVID-19 pandemic has had both positive and negative impacts on the field of controlled release drug delivery. With the urgent need for COVID-19 vaccines, there has been a significant emphasis on developing controlled release vaccine delivery systems. These systems aim to enhance vaccine efficacy, reduce the number of doses required, and improve patient compliance.

Efforts have been made to develop long-acting vaccine formulations that provide sustained immune response and eliminate the need for frequent boosters. The pandemic has led to increased funding and investment in healthcare and pharmaceutical research. This has created new opportunities for the development of controlled release drug delivery systems.

Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global controlled release drug delivery market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global controlled release drug delivery market growth over the forecast period.

Segment Analysis
The global controlled release drug delivery market is segmented based on release mechanism, technology, route of administration and region.
Auto-injectors/Needle-free injectors from Route of Administration Segment Aaccounts for 30.7% of Market Share Owing to Rising Novel Product Launches

During the projection period, targeted drug delivery is expected to dominate the market. This is mainly due to expanding demand, as well as a growing geriatric and paediatric population. For instance, In 2021, there were about 26.2 million children between the ages of 12 and 17 years old living in the United States. On the other hand, there were about 22.9 million children between the ages of zero and five years old in the country.

Additionally, when compared to typical delivery methods, targeted delivery systems achieve a longer therapeutic effect by delivering medications at the target site at predetermined drug release kinetics. Furthermore, the increasing number of product launches as a result of the increased benefits afforded by targeted delivery are likely to support the segment's growth.

Geographical Analysis
Europe Accounted for Approximately 27.4% of the Market Share
Due to increased R&D efforts and the presence of large pharmaceutical companies in the region. With an increase in patients suffering from chronic diseases such as cancer, diabetes, and COPD, the regional market is expected to grow steadily in the next years.

For instance, according to EUROSTAT, In 2020, cancer was the second highest cause of death in the EU, accounting for 1.2 million deaths, or 23.0% of all deaths in the EU. Cancer claimed a greater share of male mortality (24.9%) than female deaths (20.0%). As a result, the previously mentioned factors will dominate market growth.

Competitive Landscape
The major global players in the controlled release drug delivery market include Johnson and Johnson, Coating Place, Inc, Corium International, Inc, Depomed, Inc, Pfizer, Inc, Biogen, GlaxoSmithKline, Novartis, Orbis Biosciences, Inc., Merck and Co among others.

Why Purchase the Report?
• To visualize the global controlled release drug delivery market segmentation based on release mechanism, technology, route of administration and region,as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of controlled release drug delivery market-level with all segments.
• PDF report consists of a comprehensiveanalysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available asexcelconsisting of key products of all the major players.
The global controlled release drug delivery market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies